PRISCILLA ALVES ROCHA
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Pharmaceutical care for elderly patients in a large hospital(2022) TANAKA, C. M.; VIANA, S. S. C.; ROCHA, P. A.The aging process is often associated with the presence of multiple comorbidities and, consequently, with the presence of polypharmacy. Furthermore, older individuals usually have conditions that demand particular attention in health care, such as the presence of cognitive impairment, physiological changes, and the need for social support, which can compromise the autonomy of these individuals. The present study aimed to describe the clinical and sociodemographic profile of older patients followed up in a large hospital located in the city of São Paulo, SP, Brazil, the clinical-assistance activities developed in pharmaceutical care and points to be improved. This is a cross-sectional study, with data collection in computerized institutional systems, retrospectively, from June 2018 to July 2021. Sociodemographic and care variables related to pharmacotherapeutic follow-up were considered, where the mean age of the study population was 79 ±7 years old, with low schooling and female prevalence. An average of 5 ±2.5 comorbidities were observed per patient, using approximately 13 ± 3.4 medications and a mean pharmacotherapeutic follow-up time of 12 ±10.8 months, with a predominance of 10 months. The main points of pharmaceutical intervention were related to adherence to treatment, poor awareness about pharmacotherapy, prescriptions duplicity, and inadequate storage of medicines, among others, for which strategies were developed to solve these problems, with an emphasis on health education actions, development of medication chart and request for home glucose and blood pressure self-monitoring. In addition, the limitations found due to the lack of records of interventions with the medical team and information on loss to follow-up indicate the opportunity to improve pharmaceutical records. © 2022, Conselho Federal de Medicina. All rights reserved.
- Pharmaceutical care-based interventions in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials(2020) NOGUEIRA, Marcel; OTUYAMA, Leonardo Jun; ROCHA, Priscilla Alves; PINTO, Vanusa BarbosaObjective: To investigate the impact of pharmaceutical care-based interventions on type 2 diabetes mellitus. Methods: PubMed (R), Cochrane and Web of Science data bases were searched for randomized controlled clinical trials. Studies evaluating pharmaceutical care-based interventions in type 2 diabetes mellitus published between 2012 and 2017 were included. Glycated hemoglobin was defined as the primary endpoint; blood pressure, triglycerides and cholesterol as secondary endpoints. The random effects model was used in meta-analysis. Results: Fifteen trials involving 2,325 participants were included. Meta-analysis revealed considerable heterogeneity (I-2 >97%; p<0.001), reduction in glycated hemoglobin (-1.07%; 95%CI: -1.32; -0.83; p<0.001), glucose (-29.91mg/dL; 95%CI: -43.2; -16.6; p<0.001), triglyceride (19.8mg/dL; 95%CI: -36.6; -3.04; p=0.021), systolic blood pressure (-4.65mmHg; 95%CI: -8.9; -0.4; p=0.032) levels, and increased HDL levels (4.43mg/d; 95%CI: 0.16; 8.70; p=0.042). Conclusion: Pharmaceutical care-based clincal and education interventions have significant impact on type 2 diabetes mellitus. The tools Summary of Diabetes Self-Care Activities and the Morisky Medication Adherence Scale may be useful to monitor patients.
- Access to antiviral therapy for chronic hepatitis B during COVID-19(2022) BERTOLLI, Marilia Rocha; ROCHA, Priscilla Alves; PINTO, Vanusa Barbosa; ONO, Suzane KiokoAbstract OBJECTIVE: Hepatitis B is an important public health concern. Currently, the COVID-19 pandemic is a major challenge for health systems, and the access to pharmacologic and non-pharmacologic treatment of chronic diseases, such as hepatitis B, may have been affected due to the contingency measures. This study aimed to evaluate the access to antiviral therapy during the ongoing pandemic. METHODS: This was a descriptive analysis of the access to treatment for chronic hepatitis B at a tertiary-level university hospital in São Paulo, integrated with the Brazilian health system. The study was conducted from April to December 2020. RESULTS: Access to antiviral therapy for 225 patients was assessed. The majority of the population was male (59%). The main type of service was the Programa Medicamento em Casa (Home Medication Delivery Program), which was availed by 144 (64%) patients. Women had poorer access to antiviral therapy (56%, p<0.05), and patients registered in the HMDP (68%, p<0.05) had better access. The age group of >48 years represented 70% of the group without access to antiviral therapy. Twenty-two pharmaceutical appointments were conducted through phone calls with patients without access to antiviral therapy. CONCLUSION: This study contributes to the rationalization of efforts in a public health crisis through the identification of groups with the highest risk of poor access to antiviral therapy and the demonstration of the benefits of a medication delivery system.
conferenceObject Drug-Drug Interactions in the Era of Direct-Acting Antivirals and Clinical Outcome of Patients with Chronic Hepatitis C.(2018) NOGUEIRA, Marcel; LINO, Ana; OTUYAMA, Leonardo; LUCENA, Nayara; SANTOS, Graziella D'Agostino Ribeiro Dos; AMBROSIO, Veridiana; ROCHA, Priscilla Alves; TOLENTINO, Raphael; MARTINS, Maria Cleusa; PINTO, Vanusa Barbosa; CARRILHO, Flair Jose; ONO, Suzane Kioko